The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Zolbetuximab + pembrolizumab and chemotherapy as first-line treatment for patients with CLDN18.2-positive, HER2-negative, PD-L1-positive locally advanced unresectable or metastatic G/GEJ adenocarcinoma: Phase 3, double-blind, randomized trial (LUCERNA).
 
Kohei Shitara
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Janssen; Lilly; Ono Pharmaceutical
Consulting or Advisory Role - Abbvie; ALX Oncology; Amgen; Arcus Biosciences Inc.; Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; CMIC Co., Ltd.; Daiichi Sankyo; eChainaHealth,Inc.; Elevation Oncology; Elevation Oncology; Gilead Sciences; GlaxoSmithKline K.K.; Guardant Health; Healios; Janssen; Leap Therapeutics; Levolution Medicines,Inc.; Moderna.Inc; MSD; Novartis; Oncolys BioPharma; Ono Pharmaceutical; Phanes Therapeutics; Sanofi; Scandion Oncology; Suzuhou Liangyihui Network Technology Co.,; Takeda; Zymeworks
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Insyte Biosciences G.K., (Inst); Medpace Japan K.K., (Inst); MSD (Inst); Ono Pharmaceutical (Inst); PPD-SNBL (Inst); PRA Health Sciences (Inst); Syneos Health (Inst); Taiho Pharmaceutical (Inst); Toray Industries (Inst)
 
Peter Enzinger
Consulting or Advisory Role - ALX Oncology; Amgen; Amgen; Arcus Biosciences; Arcus Biosciences; Arcus Biosciences; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; Bayer; Bayer; BeiGene; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb/Celgene; Celgene; Chimeric Therapeutics; Chimeric Therapeutics; Coherus Biosciences; Daiichi Sankyo; Daiichi Sankyo/Astra Zeneca; Eisai; Eisai; Fosun Pharma; Gilead Sciences; Henlius; IDEAYA Biosciences; ImmPACT Bio; Jazz Pharmaceuticals; Jazz Pharmaceuticals; Legend Biotech ; Legend Biotech; Legend Biotech; Lilly; Loxo; loxo; Novartis; Novartis; Oncolys BioPharma; Oncolys BioPharma; Ono Pharmaceutical; Oxford BioTherapeutics; Regeneron; Regeneron; Sanofi; Sanofi/Aventis; SERVIER; SERVIER; Taiho Oncology; Taiho Pharmaceutical; Takeda; Takeda; Turning Point Therapeutics; Turning Point Therapeutics; Xencor; Xencor; Zymeworks
 
Florian Lordick
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; Incyte; Lilly; Merck KGaA; Merck Sharp & Dohme; Roche; SERVIER
Consulting or Advisory Role - Astellas Pharma; Boehringer Ingelheim; Bristol-Myers Squibb; Merck Sharp & Dohme; PAGE; SERVIER
Research Funding - AstraZeneca (Inst); BeOne (Inst); Daiichi Sankyo (Inst); Gilead Sciences (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly
 
Elizabeth Smyth
Employment - HCA International (I)
Honoraria - Bristol-Meyer Squibb; Novartis; Pfizer; SERVIER
Consulting or Advisory Role - Amal Therapeutics; Amgen; AstraZeneca; BeiGene; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Merck Serono; MSD; Novartis; Roche; SERVIER; Turning Point Therapeutics; Viracta Therapeutics; Zymeworks
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Bristol-Meyers Squibb (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Amgen
 
Sun Young Rha
Consulting or Advisory Role - Amgen; Arcus Biosciences; Astellas Pharma; AstraZeneca; BeOne; Daiichi Sankyo; Eisai; indivumed; LG Chem; MSD Oncology; Ono Pharmaceutical; Toray Industries
Speakers' Bureau - Amgen; Arcus Biosciences; Astellas Pharma; AstraZeneca; BeOne; BMS/Ono; Daiichi Sankyo/UCB Japan; Eisai; MSD Oncology
Research Funding - Amgen (Inst); ASLAN Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; BeiGene; BeOne (Inst); Beringer Ingelheim (Inst); Bristol-Myers Squibb; Daichii Sankyo; Eisai; Indivumed; Jazz Pharmaceuticals (Inst); Lilly; MSD Oncology; Roche/Genentech; Sillajen
 
Eric Van Cutsem
Consulting or Advisory Role - Abbvie; Agenus; ALX Oncology; Amgen; Arcus Biosciences; Astellas Pharma; AstraZeneca; Bayer; BeiGene; Bexon Clinical Consulting; BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb; Cantargia AB; Daiichi Sankyo; Debiopharm Group; Eisai; ElmediX; Fosum; Galapagos NV; GlaxoSmithKline; Ipsen; ITeos Therapeutics; Lilly; Merck KGaA; Merck Sharp & Dohme; Microbial Machines; Mirati Therapeutics; Nordic Group; Novartis; Novocure; Pfizer; Pierre Fabre; Sanofi; Seagen; SERVIER; Simcere; Taiho Pharmaceutical; Takeda; Trishula Therapeutics
 
Rui-Hua Xu
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; BeiGene; Hutchison MediPharma; Junshi Pharmaceuticals; Keymed Biosience; MSD; QiLu Pharmaceutical
 
John Strickler
Stock and Other Ownership Interests - Triumvira Immunologics, Inc
Consulting or Advisory Role - Abbvie; Alterome Therapeutics; Amgen; Astellas Pharma; AstraZeneca; Bayer; BeOne; Boehringer Ingelheim; Bristol Myers Squibb Foundation; Cytovation; Daiichi Sankyo/Astra Zeneca; Exelixis; Full-Life Technologies; GE Healthcare; GlaxoSmithKline; Incyte; Ipsen; Jazz Pharmaceuticals; Johnson & Johnson/Janssen; Leap Therapeutics; Lilly; Merck; Merck; Natera (Inst); Pfizer; Pheon Therapeutics; Quanta Therapeutics; Regeneron; Revolution Medicines; Roche/Genentech; Sanofi; Taiho Oncology; Takeda; Xilio Therapeutics; Xilio Therapeutics
Research Funding - Abbvie (Inst); Amgen (Inst); Apollo Therapeutics; AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Daiichi Sankyo/Lilly (Inst); GlaxoSmithKline (Inst); Leap Therapeutics (Inst); Lilly (Inst); Novartis; Pfizer; Quanta Therapeutics (Inst); Regeneron (Inst); Revolution Medicines (Inst); Roche/Genentech (Inst)
Expert Testimony - Seagen
 
Paul Lee
Employment - Astellas Pharma
 
Samuel Klempner
Honoraria - Merck Serono
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; BeiGene; Daiichi Sankyo/UCB Japan; Eisai; Elevation Oncology; EsoBiotec; Gilead Sciences; I-Mab; Merck; Novartis; Taiho Oncology
Research Funding - Arcus Biosciences (Inst); AstraZeneca (Inst); BeiGene (Inst); I-Mab (Inst); Leap Therapeutics (Inst); Mersana (Inst)
Other Relationship - Clinical Care Options; NCCN; Research to Practice
(OPTIONAL) Uncompensated Relationships - Debbies Dream Foundation